Table 1

Lipoprotein and fibrinogen concentrations during atorvastatin and fenofibrate therapy (n = 11).

atorvastatin
 fenofibrate

before (mg/dL)
 during (mg/dL)
 change (%)
 before (mg/dL)
 during (mg/dL)
 change (%)
Total cholesterol
 260 ± 46
 193 ± 45
 -25***
 270 ± 48
 219 ± 26
 -17***
Total triglycerides
 313 ± 198
 210 ± 63
 -11
 320 ± 190
 162 ± 48
 -42***
LDL-cholesterol
 150 ± 39
 108 ± 39
 -28**
 161 ± 48
 142 ± 23
 -7
     large, buoyant
 15.2 ± 7.1
 10.8 ± 5.4
 -27**
 17.8 ± 9.4
 14.2 ± 3.6
 -10
     intermediate dense
 57.8 ± 25.2
 42.8 ± 19.4
 -22*
 61.8 ± 29.0
 75.9 ± 20.2
 +31
     small, dense
 85.9 ± 13.4
 57.8 ± 17.5
 -23*
 91.8 ± 17.8
 61.9 ± 19.2
 -32*
HDL-cholesterol
 46.8 ± 9.4
 51.1 ± 10.4
 +15*
 50.6 ± 12.6
 55.1 ± 11.6
 +14*
Fibrinogen
 406 ± 41
 400 ± 41
 -1
 411 ± 57
 329 ± 32
 -19**

a: *p < 0.05; **p < 0.01; ***p < 0.005. b: LDL subtypes refer to following density intervals: large buoyant LDL 1.020 – 1.029 g/mL, intermediate dense LDL 1.030 – 1.034 g/mL, small dense LDL 1.041–1.066 g/mL. c: The data from 10 out of 11 patients were published previously [16].

Empen et al. Cardiovascular Diabetology 2003 2:17   doi:10.1186/1475-2840-2-17